Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- Conditions
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT04882241
- Locations
- 🇨🇳
Afflilated Hospital of Bengbu Medical College-Surgical Oncology (Site 0638), Bengbu, Anhui, China
🇨🇳Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army ( Site 0647), Xi'an, Shaanxi, China
🇨🇳Beijing Friendship Hospital ( Site 0637), Beijing, Beijing, China
No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Servicio de Salud Metropolitano Sur Oriente
- Target Recruit Count
- 73
- Registration Number
- NCT04864067
- Locations
- 🇨🇱
Complejo Asistencial Doctor Sótero del Rio, Santiago, RM, Chile
🇨🇱Hospital Padre Hurtado, Santiago, RM, Chile
🇨🇱Hospital La Florida, Santiago, RM, Chile
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
- Conditions
- Interventions
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT04859582
- Locations
- 🇨🇳
Peking Union Medical College Hospital ( Site 2425), Beijing, Beijing, China
🇨🇳Fujian Medical University Union Hospital ( Site 2410), Fuzhou, Fujian, China
🇨🇳900 Hospital of the Joint ( Site 2418), Fuzhou, Fujian, China
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
- Conditions
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT04856761
- Locations
- 🇨🇳
Huashan hospital, Shanghai, China
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 748
- Registration Number
- NCT04854668
- Locations
- 🇨🇳
The First Affiliated Hospital of ZhengZhou University, Zhengzhou, Henan, China
🇨🇳Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
🇨🇳Changzhi People's Hospital, Changzhi, Shanxi, China
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Bryan Schneider, MD
- Target Recruit Count
- 197
- Registration Number
- NCT04849364
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
🇺🇸Memorial Healthcare System, Hollywood, Florida, United States
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 124
- Registration Number
- NCT04844385
- Locations
- 🇨🇳
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 22
- Registration Number
- NCT04808323
- Locations
- 🇺🇸
Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2023-02-21
- Target Recruit Count
- 260
- Registration Number
- NCT04803539
- Locations
- 🇨🇳
Sunyat-sen Memorial Hospital, Guandong, Guangdong, China
A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT04802980
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.